These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36440022)

  • 1. Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how.
    Muthspiel M; Kaufmann CC; Burger AL; Panzer B; Verheugt FWA; Huber K
    Front Cardiovasc Med; 2022; 9():1008194. PubMed ID: 36440022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
    De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
    BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De-Escalation Dual Antiplatelet Therapy Prevail over Potent P2Y12 Inhibitor Monotherapy in Patients with Acute Coronary Syndrome Undergone Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Ding JW; Chen Y; Yu ZZ; Zhao YB; Fan KP; Yao XD; Hu LL; Liao YH; Deng TH; Xia Y; Liao HH; Yang RQ
    Rev Cardiovasc Med; 2022 Nov; 23(11):360. PubMed ID: 39076186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.
    Tavenier AH; Mehran R; Chiarito M; Cao D; Pivato CA; Nicolas J; Beerkens F; Nardin M; Sartori S; Baber U; Angiolillo DJ; Capodanno D; Valgimigli M; Hermanides RS; van 't Hof AWJ; Ten Berg JM; Chang K; Kini AS; Sharma SK; Dangas G
    Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):492-502. PubMed ID: 34459481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
    Kuno T; Watanabe A; Shoji S; Fujisaki T; Ueyama H; Takagi H; Deharo P; Cuisset T; Bangalore S; Mehran R; Stone GW; Kohsaka S; Bhatt DL
    Circ Cardiovasc Interv; 2023 Sep; 16(9):e013242. PubMed ID: 37609850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.
    Valgimigli M; Landi A; Angiolillo DJ; Baber U; Bhatt DL; Bonaca MP; Capodanno D; Cohen DJ; Gibson CM; James S; Kimura T; Lopes RD; Mehta SR; Montalescot G; Sibbing D; Steg PG; Stone GW; Storey RF; Vranckx P; Windecker S; Mehran R
    Circulation; 2024 Jul; 150(4):317-335. PubMed ID: 39038086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials.
    Shoji S; Kuno T; Ueyama H; Takagi H; Briasoulis A; Kim HS; Koo BK; Kang J; Watanabe H; Kimura T; Kohsaka S
    J Cardiol; 2024 May; 83(5):338-347. PubMed ID: 37562542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indian Perspective on De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy Study: A Knowledge, Attitude, and Practice Study among Indian Interventional Cardiologists.
    Mohan JC; Singhal A; Oomman A; Ray S; Shah VT; Nath B; Bachani D
    J Assoc Physicians India; 2024 Apr; 72(4):68-78. PubMed ID: 38881086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?
    Sabouret P; Spadafora L; Fischman D; Ullah W; Zeitouni M; Gulati M; De Rosa S; Savage MP; Costabel JP; Banach M; Biondi-Zoccai G; Galli M
    Eur J Intern Med; 2023 Apr; 110():1-9. PubMed ID: 36575107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.
    Ullah W; Zahid S; Sandhyavenu H; Faisaluddin M; Khalil F; Pasha AK; Alraies MC; Cuisset T; Rao SV; Sabouret P; Savage MP; Fischman DL
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):717-727. PubMed ID: 35325105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin-free antiplatelet strategies after percutaneous coronary interventions.
    Capranzano P; Moliterno D; Capodanno D
    Eur Heart J; 2024 Feb; 45(8):572-585. PubMed ID: 38240716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention.
    Kupka D; Sibbing D
    Korean Circ J; 2018 Oct; 48(10):863-872. PubMed ID: 30238704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
    Kamran H; Jneid H; Kayani WT; Virani SS; Levine GN; Nambi V; Khalid U
    JAMA; 2021 Apr; 325(15):1545-1555. PubMed ID: 33877270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review.
    Farag M; Jeyalan V; Ferreiro JL; Jeong YH; Geisler T; Gorog DA
    Front Cardiovasc Med; 2022; 9():1018649. PubMed ID: 36337887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2Y
    van der Sangen NM; Küçük IT; Ten Berg JM; Beijk MA; Delewi R; den Hartog AW; Appelman Y; Verouden NJ; Kikkert WJ; Henriques JP; Claessen BE
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):637-645. PubMed ID: 35916833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in East Asian Patients With Acute Coronary Syndrome.
    Li W; Zhou S; Zhang H; Wang Z; Mu G; Xie Q; Liu Z; Hua M; Cui Y; Xiang Q
    Clin Ther; 2024 Feb; 46(2):114-121. PubMed ID: 38071131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.
    Alkhalil M; Džavík V; Bhatt DL; Mehran R; Mehta SR
    Curr Cardiol Rep; 2022 Mar; 24(3):277-293. PubMed ID: 35294730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
    Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
    Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis.
    Feng WH; Chang YC; Lin YH; Chen HL; Chen CY; Lin TH; Lin TC; Chang CT; Kuo HF; Chang HM; Chu CS
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.
    Valgimigli M; Gragnano F; Branca M; Franzone A; da Costa BR; Baber U; Kimura T; Jang Y; Hahn JY; Zhao Q; Windecker S; Gibson CM; Watanabe H; Kim BK; Song YB; Zhu Y; Vranckx P; Mehta S; Ando K; Hong SJ; Gwon HC; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Calabrò P; Jüni P; Mehran R;
    JAMA Cardiol; 2024 May; 9(5):437-448. PubMed ID: 38506796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.